reviewischemic heart diseasetreatmentprevention of complicationsACE inhibitorsобзоришемическая болезнь сердцалечениепрофилактика осложненийингибиторы ангиотензинпревращающега фермента1.Чазова И. Е. Российская многоцентровая программа ПРИЗ - изучение антигипертензивной эффективности и переносимости периндоприла в широкой клинической практике. Consilium Medicum 2003; 2: 1-4.2.Carstensen S., Bonarjee V., Berning J. et al. Effects of early enalapril treatment on global and regional wall motion in acute myocardial infarction. CONSENSUS II Multi echo study group. Am. Heart J. 1995; 129: 1101-1108.3.Coder L., Torp-Pedersen C, Carlsson J. A. et al. A clinical trial of angiotensin coverting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 1995; 332: 1670-1676.4.The SOLVD investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N. Engl. J. Med. 1992; 327: 685-691.5.Пае SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 1991; 325: 293-302.6.Weidman P., Behlen M., de Courten M., Ferrari P. Antihypertensive therapy in diabetic patients. J. Hum. Hypertens. 1992; 6 (suppl. 2): S23-S26.7.The Acute Infarction Ramipril Efficacy (AIRE) study investigators. Effect of Ramipril on mortality and morbidity of survivals of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828.8.Pfeffer M., Braimwald E., Boye L. On behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 1992; 327: 669-677.9.Tatti P., Pabor M., Bington R. P. et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-603.10.Kober L., Pedersen С. Т. clinical characterization and mortality of patients screened for entry into trandalopril cardiac evalation (TRACE) study. Am. J. Cardiol. 1995; 76: 1-5.11.GISSI-3 collaboritive group. GISSI-3; effects of lisinopril and transdermal gliceril trinitrat singly and together on 6 week mortality and ventricular function after acute myocardial infarction. Lancet 1992; 343: 1115-1122.12.IS1S-4 collaboritive group. 1SIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrat, and intravenous magnesium sulfate in 58 050 patients with suspected miocardial infarction. Lancet 1995; 345: 669-685.13.Eguchi S., Matsumoto Т., Motley E. D. et al. Identification of an essential signalling cascade for nitrogen-activated protein kinase activation by angiotensin II in cultured rat vascular smooth muscle cells. J. Biol. Chem. 1996; 271: 14169-14175.14.Itoh H, Mukoyama M., Pratt R. E. et al. Multiple autocrine growth factors modulate vascular smooth muscle cell response to angiotensine II. J. Clin. Invest. 1993; 91: 2268-2278.15.Daemon M. J. A. P., Lombardi D. M., Bosnian F. Т., SchwartzS. M. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ. Res. 1991; 68: 450-456.16.Matsumoto K., Morishita R., Moriguchi A. et al. Inhibition of neointima by angiotensin converting inhibition enzyme in porcin coronary artery ballon injury model. Hypertension 2001; 37: 270-274.17.Mancini G. В., Henry G. С, Масауа С et al. Angiotensinconverting enzyme inhibition with quinapril endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND study. Circulation 1996; 94: 1490.18.Nitenberg A., Antony I. Acute effects of angiotensin-converting enzyme inhibition on coronary vasomotion in hypertensive patients. Eur. Heart. J. 1998; 19 (suppl. J): J45-J51.19.Caschin-Hemphill L., Holmvang G., Chan R. С et al. Angiotensin converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. QUIET investigators. Quinapril Ishemic Event Trial. Am. J. Cardiol. 1999; 83: 43-47.20.Drexler H., Kurs S., Jeserich M. et al. Effects of chronic angiotensinconverting enzyme inhibition on endothelial function in patients with chronic heart failure. Am. J. Cardiol. 1995; 76: 13E-18E.21.Weber C, Weber K., Weber P. С Increased adhesivness of isolated monocytes to endothelium is prevented by vitamin С intake in smokers. Circulation 1996; 93: 1488-1492.22.Schwarzkopf В., Brehm M., Mundhenke M., Strauer В. Е. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension 2000; 36: 220-225.23.Vaughan D. E., Declerk P. J., Vanhoutte P. et al. Reactivated recombinant plasminogen activator inhibitor-1 (rPAl-1) effectively prevents trombolysis in vivo. Thromb. Haemost. 1992; 68: 60-63.24.Козиолова Н. А., Щекотов В. В. Оценка эффективности периндоприла в лечении больных стенокардией, рефрактерной к антиангинальной терапии. В кн.: Человек и лекарство: Тезисы докладов VII Российского нац. конгресса. М.: 2000. 124.25.Morishita Т., Masato Т., Shimokawa H. et al. Long-term treatment with perindopril amilorates dobutamine induced myocardial ischemia in patients with coronary artery disease. Jpn. J. Pharmacol. 2002; 88: 100-107.26.Dzau V. J. Mechanism of protective effects of ACE inhibition on coronary artery disease. Eur. Heart. J. 1998; 19 (suppl. J): J2-J6.27.Бритое А. Н. Ингибиторы ангиотензинпревращающего фермента в профилактике инсульта: уроки программы "PROGRESS". Кардиоваск. тер. и профилакт. 2002; 1: 58- 64.28.Чазова И. Е., Дмитриев В. В. Предотвращение повторного инсульта возможно (результаты исследования PROGRESS). Consilium Medicum 2001; 10: 3-6.29.PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transistent ischemic attack. Lancet 2001; 358: 1033-1041.30.Asmar R. G., Pannier В., Santoni et al. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. Circulation 1988; 78: 941-950.31.Sihm I., Schroeder A. P., Aalrjaer С et al. Normalization of cardiovascular structure during antihypertensive treatment with a regimen based on the ACE-inhibitor perindopril. Blood pressure, 1995; 4: 241-248.32.Мычка В. Б., Масенко М. Т., Творогова М. Г. и др. Применение периндоприла у больных мягкой и умеренной артериальной гипертензией и метаболическим синдромом. Артер. гипертенз. 1998; 1: 26-28.33.Некрутенко Л. А., Маланьина К. С, Хлынова О. В. Влияние престариума на сосудисто-тромбоцитарный гемостаз у больных гипертонической болезнью. В кн.: Человек и лекарство: Тезисы докладов V Российского нац. конгресса. М.; 1998. 130.34.Nakashima M., Mombouli J. V., Taylor A. A., Vanhoute P. M. Endotheliumdependent hyperpolarization caused by bradikinin in human coronary arteries. J. Clin. Invest. 1993; 92: 2867-2871.35.Fox К. М. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 832-833.36.The HOPE Study investigators. Effects of an angiotensin converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in highrisk patients. N. Engl. J. Med. 2000; 342: 145-153.